GE HealthCare Completes Acquisition of Nihon Medi-Physics (NMP), a Leading Radiopharmaceutical Company in Japan
GE HealthCare (GEHC) has completed its acquisition of Sumitomo Chemical's 50% stake in Nihon Medi-Physics (NMP), giving it full ownership of the Japanese radiopharmaceutical company. NMP, which generated revenues of 28.2B JPY (~$183M) in 2023, specializes in developing and manufacturing radiopharmaceuticals for SPECT and PET molecular imaging procedures.
Kevin O'Neill, President & CEO of GE HealthCare's Pharmaceutical Diagnostics segment, will also become President of NMP. The company expects this transaction to be neutral to Adjusted EPS in year one and accretive thereafter. The acquisition positions NMP to enhance patient access to next-generation radiopharmaceuticals in Japan, which is projected to become a leader in the $7 billion molecular imaging global market.
GE HealthCare (GEHC) ha completato l'acquisizione del 50% di partecipazione di Sumitomo Chemical in Nihon Medi-Physics (NMP), ottenendo così la piena proprietà della compagnia giapponese di radiofarmaceutici. NMP, che ha generato ricavi di 28,2 miliardi di JPY (~183 milioni di dollari) nel 2023, si specializza nello sviluppo e nella produzione di radiofarmaceutici per procedure di imaging molecolare SPECT e PET.
Kevin O'Neill, Presidente e CEO del segmento Diagnostica Farmaceutica di GE HealthCare, diventerà anche Presidente di NMP. L'azienda si aspetta che questa transazione sia neutra per l'EPS rettificato nel primo anno e accrescitiva in seguito. L'acquisizione posiziona NMP per migliorare l'accesso dei pazienti a radiofarmaceutici di nuova generazione in Giappone, che si prevede diventerà un leader nel mercato globale dell'imaging molecolare da 7 miliardi di dollari.
GE HealthCare (GEHC) ha completado la adquisición del 50% de participación de Sumitomo Chemical en Nihon Medi-Physics (NMP), obteniendo así la propiedad total de la compañía japonesa de radiofármacos. NMP, que generó ingresos de 28.2 mil millones de JPY (~183 millones de dólares) en 2023, se especializa en el desarrollo y fabricación de radiofármacos para procedimientos de imagen molecular SPECT y PET.
Kevin O'Neill, Presidente y CEO del segmento de Diagnósticos Farmacéuticos de GE HealthCare, también se convertirá en Presidente de NMP. La compañía espera que esta transacción sea neutral para el EPS ajustado en el primer año y accretiva a partir de entonces. La adquisición posiciona a NMP para mejorar el acceso de los pacientes a radiofármacos de próxima generación en Japón, que se proyecta se convertirá en un líder en el mercado global de imagen molecular de 7 mil millones de dólares.
GE HealthCare (GEHC)는 Nihon Medi-Physics (NMP)에 대한 Sumitomo Chemical의 50% 지분 인수를 완료하여 일본의 방사선 의약품 회사에 대한 완전한 소유권을 확보했습니다. NMP는 2023년에 282억 JPY (~1억 8300만 달러)의 수익을 올렸으며, SPECT 및 PET 분자 이미징 절차를 위한 방사선 의약품의 개발 및 제조를 전문으로 합니다.
GE HealthCare의 제약 진단 부문 사장 겸 CEO인 Kevin O'Neill이 NMP의 사장으로도 취임할 것입니다. 회사는 이번 거래가 첫 해에는 조정된 EPS에 중립적일 것으로 예상하며, 이후에는 증가할 것으로 보입니다. 이번 인수는 NMP가 일본에서 차세대 방사선 의약품에 대한 환자 접근을 향상시킬 수 있는 위치에 놓이게 하며, 일본은 70억 달러 규모의 글로벌 분자 이미징 시장의 선두주자가 될 것으로 예상됩니다.
GE HealthCare (GEHC) a finalisé l'acquisition de la participation de 50 % de Sumitomo Chemical dans Nihon Medi-Physics (NMP), lui donnant ainsi la pleine propriété de l'entreprise japonaise de radio-pharmaceutiques. NMP, qui a généré des revenus de 28,2 milliards de JPY (~183 millions de dollars) en 2023, est spécialisée dans le développement et la fabrication de radio-pharmaceutiques pour les procédures d'imagerie moléculaire SPECT et PET.
Kevin O'Neill, Président et CEO du segment Diagnostiques Pharmaceutiques de GE HealthCare, deviendra également Président de NMP. L'entreprise s'attend à ce que cette transaction soit neutre pour le BPA ajusté la première année et accretive par la suite. L'acquisition positionne NMP pour améliorer l'accès des patients aux radio-pharmaceutiques de nouvelle génération au Japon, qui devrait devenir un leader sur le marché mondial de l'imagerie moléculaire de 7 milliards de dollars.
GE HealthCare (GEHC) hat die Übernahme des 50% Anteils von Sumitomo Chemical an Nihon Medi-Physics (NMP) abgeschlossen und damit die vollständige Eigentümerschaft des japanischen Radiopharmazeutikums erlangt. NMP, das im Jahr 2023 Einnahmen von 28,2 Milliarden JPY (~183 Millionen USD) generierte, ist auf die Entwicklung und Herstellung von Radiopharmazeutika für SPECT- und PET-Molekularbildverfahren spezialisiert.
Kevin O'Neill, Präsident und CEO des Pharmadiagnostiksegments von GE HealthCare, wird auch Präsident von NMP. Das Unternehmen erwartet, dass diese Transaktion im ersten Jahr neutral für das bereinigte EPS sein wird und danach wertsteigernd wirkt. Die Übernahme positioniert NMP, um den Patienten in Japan den Zugang zu neuartigen Radiopharmazeutika zu erleichtern, wobei Japan voraussichtlich ein führender Anbieter im 7-Milliarden-Dollar-Markt für molekulare Bildgebung werden wird.
- Full ownership acquisition provides complete control over NMP's operations and revenue stream
- Strategic expansion in Japan's growing molecular imaging market
- Transaction expected to be earnings accretive after first year
- Immediate revenue contribution of $183M annually
- Enhanced market position in radiopharmaceuticals for neurology, cardiology, and oncology
- Transaction neutral to EPS in first year, indicating no immediate earnings benefit
- Integration costs and business disruption risks highlighted in forward-looking statements
- Potential challenges in maintaining relationships with employees, customers, and suppliers noted
Insights
GE HealthCare's acquisition of the remaining 50% stake in Nihon Medi-Physics (NMP) represents a strategic move to gain complete control over a specialized radiopharmaceutical company in Japan. With this transaction, GE HealthCare secures full ownership of a business generating
The financial impact appears measured and prudent - management expects the acquisition to be neutral to Adjusted EPS in year one and accretive thereafter. While NMP's revenue contribution is relatively modest compared to GE HealthCare's
This acquisition completes a long-term investment strategy that began in 2004 when GE acquired Amersham plc and its 50% stake in NMP. By installing the President of GE HealthCare's Pharmaceutical Diagnostics segment as President of NMP, the company is positioning for operational integration and potential synergies between their imaging equipment and radiopharmaceutical businesses.
From an investor perspective, this represents a calculated expansion in a specialized growth segment without significant near-term financial risk. The transaction strengthens GE HealthCare's vertical integration in diagnostic imaging and enhances its competitive positioning against other medical technology companies in the Asia-Pacific region.
GE HealthCare's acquisition of full ownership in NMP significantly strengthens its position in the radiopharmaceutical space, particularly for molecular imaging diagnostic applications. Radiopharmaceuticals are specialized imaging agents that enable highly detailed visualization of biological processes at the cellular level, offering superior diagnostic capabilities compared to conventional imaging methods.
NMP's expertise in SPECT and PET molecular imaging agents positions GE HealthCare to capitalize on the growing demand for precision diagnostics across neurology, cardiology, and oncology. These imaging modalities are increasingly critical for early disease detection, treatment monitoring, and personalized medicine approaches.
The Japanese market represents a strategic foothold in Asia, with Japan emerging as a center of excellence for radiopharmaceuticals. This acquisition provides GE HealthCare with expanded manufacturing capabilities and distribution networks for both existing products and next-generation imaging agents.
By vertically integrating NMP's radiopharmaceutical development and production with GE HealthCare's existing imaging equipment business, the company can offer more comprehensive diagnostic solutions to healthcare providers. This creates potential for bundled offerings that combine imaging hardware with the specialized radiopharmaceutical agents required for advanced diagnostic procedures.
The timing is opportune as molecular imaging continues to grow in importance for detecting diseases earlier and with greater precision, driving more effective treatment decisions and better patient outcomes.
-
GE HealthCare has completed its acquisition of Sumitomo Chemical’s
50% stake in Nihon Medi-Physics (NMP), giving it full ownership. -
As part of GE HealthCare, NMP, already a leading radiopharmaceutical company in
Japan , is positioned to enhance patient access to next-generation radiopharmaceuticals that enable detection and diagnosis of disease - Kevin O’Neill, President & CEO of GE HealthCare’s Pharmaceutical Diagnostics segment, will also become President of NMP.
Nihon Medi-Physics headquarters and radiopharmaceutical imaging agents about to go through labelling and packing process.
Kevin O’Neill, President & CEO of GE HealthCare’s Pharmaceutical Diagnostics (PDx) segment, who will also become President of NMP, said: “We are delighted to welcome Nihon Medi-Physics to GE HealthCare, increasing our existing footprint and offering in
NMP’s product portfolio includes GE HealthCare radiopharmaceuticals used to enable molecular imaging across neurology, cardiology and oncology procedures. NMP, headquartered in
The Company expects this transaction to be neutral to Adjusted EPS2 in year one and accretive thereafter.
GE HealthCare was advised by Solomon Partners Securities, LLC.
The intent to acquire the remaining
Forward-Looking Statements
This release contains forward-looking statements. These forward-looking statements might be identified by words, and variations of words, such as “will,” “expect,” “may,” “would,” “could,” “plan,” “believe,” “anticipate,” “intend,” “estimate,” “potential,” “position,” and similar expressions. These forward-looking statements may include, but are not limited to, statements about the transaction, the expected results of the transaction, future market conditions, and the Company’s performance, growth opportunities, and strategy. These forward-looking statements involve risks and uncertainties, many of which are beyond the control of the Company. Factors that could cause the Company’s actual results to differ materially from those described in its forward-looking statements include, but are not limited to, the Company may be unable to achieve the anticipated benefits of the transaction; operating costs and business disruptions (including, without limitation, difficulties in maintaining relationships with employees, customers, and suppliers) may be greater than expected; and the Company may assume unexpected risks and liabilities. Other factors that may cause such a difference also include those discussed in the "Risk Factors" section of the Company’s Annual Report on Form 10-K filed with the
About GE HealthCare Technologies Inc.
GE HealthCare is a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, dedicated to providing integrated solutions, services, and data analytics to make hospitals more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, connected, and compassionate care, while simplifying the patient’s journey across the care pathway. Together our Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics businesses help improve patient care from diagnosis, to therapy, to monitoring. We are a
GE HealthCare is proud to be among 2025 Fortune World’s Most Admired Companies™.
Follow us on LinkedIn, X, Facebook, Instagram, and Insights for the latest news, or visit our website https://www.gehealthcare.com for more information.
1 GE HealthCare estimated global end markets as of December 2023, and estimated market CAGR 2024–2028.
2 Non-GAAP financial measure. See our earnings release dated February 13, 2025 for the definition of Adjusted EPS.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250330506353/en/
Media contact
David Morris
Executive, Communications, Pharmaceutical Diagnostics
GE HealthCare
+44 7920591370
david.j.morris@gehealthcare.com
Source: GE HealthCare Technologies Inc.
FAQ
What is the revenue of Nihon Medi-Physics (NMP) that GEHC acquired?
How will the NMP acquisition affect GEHC's earnings per share?
What is the size of the molecular imaging market that GEHC is targeting?
What products does NMP offer in GEHC's portfolio?
When was NMP founded and what was GEHC's previous ownership stake?
